Accueil   Diary - News   All news Transgene annonces publication

Transgene annonces publication

Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer.



Transgene SA (Euronext: TNG) today announced that the results from the Phase 2b part of the Phase 2b/3 TIME trial with TG4010 immunotherapy in non-small cell lung cancer (NSCLC) have been published in the peer-reviewed medical journal, The Lancet Oncology. The article, entitled “TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial,” by E. Quoix et al is now available online.